OncoTargets and Therapy (Jul 2018)

The role of histone lysine methyltransferase NSD3 in cancer

  • Han X,
  • Piao L,
  • Zhuang Q,
  • Yuan X,
  • Liu Z,
  • He X

Journal volume & issue
Vol. Volume 11
pp. 3847 – 3852

Abstract

Read online

Xu Han,1,* Lianhua Piao,2,* Qianfeng Zhuang,1 Xiaofeng Yuan,3 Zhiwei Liu,3 Xiaozhou He1 1Department of Urology, The Third Affiliated Hospital of Soochow University, 2Institute of Bioinformatics and Medical Engineering, Jiangsu University of Technology, 3Department of Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, People’s Republic of China *These authors contributed equally to this work Abstract: The growing number of findings demonstrate that nuclear receptor suppressor of variegation, enhancer of zeste, and trithorax domain-containing 3 (NSD3) is amplified and overexpressed in multiple cancer types. Nevertheless, the biological roles of NSD3 in carcinogenesis have not been well understood. In this review, we summarize the current knowledge on the mechanisms underlying NSD3 regulation in different cancers. In addition, NSD3 may serve as a potential druggable target for selective cancer therapy in the future. Keywords: NSD3, cancer, carcinogenesis

Keywords